Enveda Secures $311M to Bring Nature-Derived AI Drugs Into Clinical Trials
AI biotech startup Enveda has raised $311 million in a funding round valuing the company at $2 billion as it advances natural-source drug candidates.
Enveda, a biotech company leveraging artificial intelligence to discover nature-derived drugs, has successfully raised $311 million in a fresh funding round. This significant investment values the AI biotech startup at $2 billion.
The newly secured capital will enable the company to advance its pipeline of novel therapeutics into clinical trials. Enveda is currently testing treatments aimed at skin conditions and preserving weight loss after stopping GLP-1 medications.
By combining advanced artificial intelligence with nature's vast chemical diversity, Enveda accelerates the identification and development of potent drug candidates. The technology effectively streamlines the traditionally slow process of pharmaceutical discovery.
This milestone highlights the growing impact of artificial intelligence on the life sciences and healthcare sectors. As AI-driven biotech continues to mature, it promises to revolutionize drug discovery and bring advanced medical solutions to global markets faster than ever before.
